hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-26 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
A first-in-class medication is a prototype drug that uses a "new and unique mechanism of action" to treat a particular medical condition. While the Food and Drug Administration's Center for Drug Evaluation and Research tracks first-in-class medications and reports on them annually, first-in-class is not considered a regulatory category. Although many first-in-class medications qualify as breakthrough therapies, Regenerative Medicine Advanced Therapies or orphan drugs, first-in-class status itself has no regulatory effect.
== Early life and education == Sandra Pizzarello was born in Venice, Italy on 24 April 1933. In 1955, she graduated summa cum laude from the University of Padua earning her Doctor of Biological Sciences degree under her adviser Professor Roncato. Pizzarello went on to work as a research associate developing tranquilizers for Farmitalia Research Laboratories in the Department of Neuropharmacology. Over the course of several years, Pizzarello transitioned from research to raising a family. Following a career opportunity for her husband, an aeronautical engineer and computer scientist, she moved her family to Phoenix, Arizona in 1970. Once Pizzarello's youngest of four children finished primary school, her focus returned to her career after a decade away from scientific research. She audited a graduate biochemistry seminar course at ASU where she met Professor John Read Cronin, future co-discoverer of amino acid enantiomeric excess in meteorites. Due to her outstanding performance in the course, she was offered a job to work with Cronin at the university as a research professor in analyzing the recently recovered Murchison meteorite. Sandra Pizzarello died on 24 October 2021, at the age of 88.
The third case studied here is alpha-methylfentanyl. This group contains a substitution similar to the 3-methylfentanyl that was examined in the previous example on the previous image in this series (Fentanyl Synthesis p4.png), but it is on the phenethyl chain as opposed to being implanted on the piperidine ring. We then mark the two stereocenters, one on the C-4 carbon just as on fentanyl itself, and the other on the C-α (alpha carbon). To analogize these stereocenters we chose N-(1-hydroxyethyl)-4-hydroxypiperidine. When we draw out all potential stereoisomers, we see that the C-4 stereocenter is super-imposable, eliminating it as a true stereocenter. This leaves only 2 R/S assignments that follow the orientation of the stereocenter at the C-α (alpha carbon) position for the real α-methylfentanyl. These are labeled 7S and 7R, a reflection of the stereocenter in the piperidine derivative we used being at C-7 position. It is interesting that the C-4 stereocenter, which has no chiral activity in fentanyl (1st example), activiates it in 3-methylfentanyl with an on-the-ring addition, and loses it again in α-methylfentanyl with an off-the-ring addition. The fourth case studied here is ohmfentanyl. Ohmfentanyl has three potential stereocenters, which are best analogized by another piperidine derivative: N-(1-hydroxyethyl)-3-methyl-4-hydroxypiperidine. This uses a similar structure to analogize the three potential stereocenters in ohmfentanyl, namely the 4-C, the 3-C, and the β-C (beta carbon). These three stereocenters are analogized in the C-4, C-3, and C-7 respectively.
Sources: en.wikipedia.org
Heseltine was being quietly urged to challenge Thatcher for the party leadership by David Mellor, the Arts Minister, but in a carefully worded formula Heseltine had repeatedly insisted that he could "not foresee ... circumstances" in which he would do so. Then came the Conservative defeat at the Eastbourne by-election (18 October) and the resignation of Deputy Prime Minister Geoffrey Howe (1 November). Heseltine wrote a six-page public letter to his local Association chairman, calling for more regard for the wide range of opinions in the party. Heseltine then left for the Middle East to visit King Hussein of Jordan and Israeli Prime Minister Yitzhak Shamir. Association officers sent him a 97-word reply (5 November) saying that they supported Thatcher's leadership. The party's regional agent had been present at their meeting, but they insisted he had not interfered with their reply. Round about the same time Thatcher's press secretary Bernard Ingham briefed journalists that Heseltine had "lit the blue touch paper then retired", although he denied having demanded that Heseltine "put up or shut up"; the Daily Mail front page asked "does he have the courage?" and The Times commented that if he did not throw his hat into the ring he would deserve to have it "stuffed down his throat". Thatcher brought the annual leadership election forward by a fortnight, causing Alastair Campbell to write in the Daily Mirror that "Tarzan the Tory Ape Man had made a right monkey of himself".
A single-domain antibody (sdAb), also known as a Nanobody, is an antibody fragment consisting of a single monomeric variable antibody domain. Like a whole antibody, it is able to bind selectively to a specific antigen. With a molecular weight of only 12–15 kDa, single-domain antibodies (sdAbs) are much smaller than common antibodies (150–160 kDa) which are composed of two heavy protein chains and two light chains, and even smaller than Fab fragments (~50 kDa, one light chain and half a heavy chain) and single-chain variable fragments (~25 kDa, two variable domains, one from a light and one from a heavy chain). The first single-domain antibodies were engineered from heavy-chain antibodies found in camelids at the Université Libre de Bruxelles; these are called VHH fragments. Cartilaginous fish also have heavy-chain antibodies (IgNAR, 'immunoglobulin new antigen receptor'), from which single-domain antibodies called VNAR fragments can be obtained. An alternative approach is to split the dimeric variable domains from common immunoglobulin G (IgG) from humans or mice into monomers. Although most research into single-domain antibodies is currently based on heavy chain variable domains, nanobodies derived from light chains have also been shown to bind specifically to target epitopes. Camelid nanobodies have been shown to be just as specific as antibodies, and in some cases they are more robust. They are easily isolated using the same phage panning procedure used for antibodies, allowing them to be cultured in vitro in large concentrations.
=== Peripheral tissues === Neuronostatin/GPR107 signaling is associated with regulation of COL4 within both breast cancer and kidney tissues, where Neuronostatin/GPR107 reduces expression of COL4. In breast cancer, this reduction in COL4 generates enlarged pores within the extracellular matrix that allow for increase breast cancer migration and proliferation, leading to increased rates of metastasis. Neuronostatin and GPR107 have similarly been linked to increased rates of migration within prostate cancer. Within kidney tissues, Neuronostatin/GPR107 reduces thickening/remodeling of the glomerular basement membrane by reducing COL4 deposition and improves features of diabetic nephropathy Additional features of Neuronostatin signaling include regulation of cardiomyocytes; Neuronostatin depresses cardiomyocyte function by affecting [Ca2+]i responses and regulating the expression of calcium regulating proteins
== External links == Adrenomedullin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human ADM genome location and ADM gene details page in the UCSC Genome Browser. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
In bacteria, selection from ~108 random-sequence genes identified many variants that promote E. coli growth under stress, including a random protein (RamF) that interacts with chaperones to drive degradation of a toxin and can be improved by beneficial mutations. Similarly, screening ~100 million short (semi-)random sequences for phage resistance uncovered thousands of novel genes that protect E. coli through distinct mechanisms, showing that unrelated random sequences can converge on similar adaptive phenotypes. Experiments in E. coli showed that random peptides tended to have more benign effects when they were enriched for amino acids that were small, and that promoted intrinsic structural disorder. Comparative work in flies indicates that de novo-originated genes can become integrated into gene regulatory networks through interactions with key transcription factors, potentially contributing to lineage-specific developmental trajectories ("developmental system drift").
=== Psychology === The psychological studies Body Image Concerns of Breast Augmentation Patients (2003) and Body Dysmorphic Disorder and Cosmetic Surgery (2006) indicate that women who seek breast-augmentation surgery usually have a mental-health background that features treatments of psychotherapy, who suffer many occurrences low self-esteem and of psychological depression, in comparison with the general population of women. Moreover, women who sought breast augmentation also suffered body dysmorphia, which is an extreme dissatisfaction and preoccupation with perceived physical defects in her personal appearance, which misperceptions often lead to significant impairment of her mental ability to function socially. Post-operative patient surveys about the mental health and the quality of life of the women, reported improved physical health, physical appearance, social life, self-confidence, self-esteem, and satisfaction with sexual functioning. Furthermore, most of the women reported long-term satisfaction with their breast implants; some despite having had medical complications that required surgical revision, either corrective or aesthetic. In Denmark, 8.0 percent of breast augmentation patients had a pre-operative history of psychiatric hospitalization.
== Live Well Foundation philanthropy == In 2022, GNC Live Well Foundation partnered with Filmrise and director Nate Boyer to support his first film "MVP", while also holding a fundraising campaign for Boyer's nonprofit organization, Merging Vets & Players. The GNC Live Well Foundation is also the national sponsor for the film throughout the 2022-23 NFL season. With a stated mission to encourage and assist people in living well, the company has donated over $1 million to MVP in December 2020. This nonprofit organization was founded by Jay Glazer and Nate Boyer in 2015 in order to address the challenges that military veterans and retired athletes face when transitioning to civilian life. Starting from December 2020, the company has made a donation that exceeds $1 million to Merging Vets and Players (MVP). Jay Glazer, a Fox Sports NFL Insider, and Nate Boyer, a former green beret and Seattle Seahawk, established MVP in 2015. The goal of the non-profit organization is to tackle the difficulties that combat veterans and former professional athletes encounter as they transition to civilian life after leaving their respective professions. While the foundation aims to improve public health through its various initiatives, its association with GNC raises questions about its independence and the authenticity of its objectives.
=== Heavy metals present in the clinker === The presence of heavy metals in the clinker arises both from the natural raw materials and from the use of recycled by-products or alternative fuels. The high pH prevailing in the cement porewater (12.5 < pH < 13.5) limits the mobility of many heavy metals by decreasing their solubility and increasing their sorption onto the cement mineral phases. Nickel, zinc and lead are commonly found in cement in non-negligible concentrations. Chromium may also directly arise as natural impurity from the raw materials or as secondary contamination from the abrasion of hard chromium steel alloys used in the ball mills when the clinker is ground. As chromate (CrO42−) is toxic and may cause severe skin allergies at trace concentration, it is sometimes reduced into trivalent Cr(III) by addition of ferrous sulfate (FeSO4).
Teleradiology is the transmission of radiographic images from one location to another for interpretation by an appropriately trained professional, usually a radiologist or reporting radiographer. It is most often used to allow rapid interpretation of emergency room, ICU, and other emergent examinations after hours of usual operation, at night, and on weekends. In these cases, the images can be sent across time zones (e.g., to Spain, Australia, India) with the receiving Clinician working her normal daylight hours. However, at present, large private teleradiology companies in the U.S. provide most after-hours coverage employing night-working radiologists. Teleradiology can also be used to obtain consultation with an expert or subspecialist about a complicated or puzzling case. In the U.S., many hospitals outsource their radiology departments to radiologists in India due to the lowered cost and availability of high-speed internet access. Teleradiology requires a sending station, a high-speed internet connection, and a high-quality receiving station. At the transmission station, plain radiographs are passed through a digitizing machine before transmission, while CT, MRI, ultrasound, and nuclear medicine scans can be sent directly, as they are already digital data. The computer at the receiving end will need to have a high-quality display screen that has been tested and cleared for clinical purposes. Reports are then transmitted to the requesting clinician.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.